AlphaRose Therapeutics

AlphaRose Therapeutics

Open  for investment

About this raise

AlphaRose Therapeutics, with a valuation of $12.09 million, is raising funds on StartEngine. The company is pioneering personalized medicine for children with rare genetic diseases. AlphaRose Therapeutics rapidly develops and commercializes treatments for children with generic diseases and is focused on neurodevelopmental conditions using its antisense oligonucleotide technology. The company has already developed a proprietary treatment for genetic mutations in HNRNPH2, Rosiphersen, and has a developing pipeline identified by its AI program Argus. Casey McPherson founded AlphaRose Therapeutics in October 2023. The current crowdfunding campaign has a minimum target of $123,998.85 and a maximum target of $1.23 million. The campaign proceeds will be used for research and development, company employment, and working capital.

Expand

Investment Overview

Committed this round: $1,138,327

Deal Terms

Total Commitments ($USD)

Platform
StartEngine
Start Date
01/29/2025
Close Date
04/30/2025
Min. Goal
$123,999
Max Goal
$1,234,998
Min. Investment

$599

Security Type

Equity - Common

Series

Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$1.35

Pre-Money Valuation

$12,089,089

Company & Team

Company

Year Founded
2023
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2B2C
Margin
Medium
Capital Intensity
High
Location
Austin, Texas
Business Type
Growth
Company Website
Visit Website

Team

Employees
2
Prior Founder Exits?
No
Founder Name
Casey McPherson
Title
CEO

Financials

as of November 1, 2024
 Revenue
$0
 Monthly Burn
$45,000
 Runway
15 months

Summary Profit and Loss Statement

FY 2023 FY 2022

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-406,429

$0

Summary Balance Sheet

FY 2023 FY 2022

Cash

$682,327

$0

Accounts Receivable

$0

$0

Total Assets

$682,327

$0

Short-Term Debt

$38,756

$0

Long-Term Debt

$1,050,000

$0

Total Liabilities

$1,088,756

$0

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Total Prior Capital Raised
$1,070,000
VC Backed?
No
Close Date Platform Valuation Total Raised Security Type Status Reg Type
04/30/2025 StartEngine $12,089,089 $1,138,327 Equity - Common Active RegCF
Create a free account today to gain access to Kingscrowd analytics.
Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
AlphaRose Therapeutics on StartEngine 2025
Platform: StartEngine
Security Type: Equity - Common
Valuation: $12,089,089
Price per Share: $1.35

Follow company

Follow AlphaRose Therapeutics on StartEngine 2025

Buy AlphaRose Therapeutics's Deal Report

AlphaRose Therapeutics Deal Report

Get Kingscrowd's comprehensive report on AlphaRose Therapeutics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether AlphaRose Therapeutics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the AlphaRose Therapeutics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge